• Je něco špatně v tomto záznamu ?

Human galectin‐3: Molecular switch of gene expression in dermal fibroblasts in vitro and of skin collagen organization in open wounds and tensile strength in incisions in vivo

P. Gál, T. Vasilenko, I. Kováč, M. Čoma, J. Jakubčo, M. Jakubčová, V. Peržeľová, L. Urban, M. Kolář, F. Sabol, J. Luczy, M. Novotný, J. Majerník, HJ. Gabius, KJ. Smetana

. 2021 ; 23 (2) : . [pub] 20201210

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019361

Understanding the molecular and cellular processes in skin wound healing can pave the way for devising innovative concepts by turning the identified natural effectors into therapeutic tools. Based on the concept of broad‐scale engagement of members of the family of galactoside‐binding lectins (galectins) in pathophysiological processes, such as cancer or tissue repair/regeneration, the present study investigated the potential of galectins‐1 (Gal‐1) and ‐3 (Gal‐3) in wound healing. Human dermal fibroblasts, which are key cells involved in skin wound healing, responded to galectin exposure (Gal‐1 at 300 or Gal‐3 at 600 ng/ml) with selective changes in gene expression among a panel of 84 wound‐healing‐related genes, as well as remodeling of the extracellular matrix. In the case of Gal‐3, positive expression of Ki67 and cell number increased when using a decellularized matrix produced by Gal‐3‐treated fibroblasts as substrate for culture of interfollicular keratinocytes. In vivo wounds were topically treated with 20 ng/ml Gal‐1 or ‐3, and collagen score was found to be elevated in excisional wound repair in rats treated with Gal‐3. The tensile strength measured in incisions was significantly increased from 79.5±17.5 g/mm2 in controls to 103.1±21.4 g/mm2 after 21 days of healing. These data warrant further testing mixtures of galectins and other types of compounds, for example a combination of galectins and TGF‐β1.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019361
003      
CZ-PrNML
005      
20240716102518.0
007      
ta
008      
210728s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/mmr.2020.11738 $2 doi
035    __
$a (PubMed)33300056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Gál, Peter, $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic $d 1981- $7 xx0320027
245    10
$a Human galectin‐3: Molecular switch of gene expression in dermal fibroblasts in vitro and of skin collagen organization in open wounds and tensile strength in incisions in vivo / $c P. Gál, T. Vasilenko, I. Kováč, M. Čoma, J. Jakubčo, M. Jakubčová, V. Peržeľová, L. Urban, M. Kolář, F. Sabol, J. Luczy, M. Novotný, J. Majerník, HJ. Gabius, KJ. Smetana
520    9_
$a Understanding the molecular and cellular processes in skin wound healing can pave the way for devising innovative concepts by turning the identified natural effectors into therapeutic tools. Based on the concept of broad‐scale engagement of members of the family of galactoside‐binding lectins (galectins) in pathophysiological processes, such as cancer or tissue repair/regeneration, the present study investigated the potential of galectins‐1 (Gal‐1) and ‐3 (Gal‐3) in wound healing. Human dermal fibroblasts, which are key cells involved in skin wound healing, responded to galectin exposure (Gal‐1 at 300 or Gal‐3 at 600 ng/ml) with selective changes in gene expression among a panel of 84 wound‐healing‐related genes, as well as remodeling of the extracellular matrix. In the case of Gal‐3, positive expression of Ki67 and cell number increased when using a decellularized matrix produced by Gal‐3‐treated fibroblasts as substrate for culture of interfollicular keratinocytes. In vivo wounds were topically treated with 20 ng/ml Gal‐1 or ‐3, and collagen score was found to be elevated in excisional wound repair in rats treated with Gal‐3. The tensile strength measured in incisions was significantly increased from 79.5±17.5 g/mm2 in controls to 103.1±21.4 g/mm2 after 21 days of healing. These data warrant further testing mixtures of galectins and other types of compounds, for example a combination of galectins and TGF‐β1.
650    _2
$a krevní proteiny $x biosyntéza $7 D001798
650    _2
$a kolagen $x biosyntéza $7 D003094
650    _2
$a škára $x metabolismus $x patologie $7 D020405
650    _2
$a fibroblasty $x metabolismus $x patologie $7 D005347
650    _2
$a galektiny $x biosyntéza $7 D037161
650    12
$a regulace genové exprese $7 D005786
650    _2
$a lidé $7 D006801
650    12
$a pevnost v tahu $7 D013718
650    _2
$a rány a poranění $x metabolismus $x patologie $7 D014947
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vasilenko, Tomáš $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Kováč, Ivan $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Čoma, Matúš $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic $7 xx0264880
700    1_
$a Jakubčo, Ján $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Jakubčová, Martina $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Peržeľová, Vlasta $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Urban, Lukáš $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Kolář, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Sabol, František $u Department of Heart Surgery, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Luczy, Ján $u Department of Heart Surgery, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Novotný, Martin $u Department of Biomedical Research, East‐Slovak Institute of Cardiovascular Diseases, 040 66 Košice, Slovak Republic
700    1_
$a Majerník, Jaroslav $u Department of Medical Informatics, Faculty of Medicine, Pavol Jozef Šafárik University, 040 66 Košice, Slovak Republic
700    1_
$a Gabius, Hans-Joachim $u Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig‐Maximilian‐University, D‐80539 Munich, Germany
700    1_
$a Smetana, Karel Jr $u Institute of Anatomy, First Faculty of Medicine, Charles University, 128 00 Prague
773    0_
$w MED00181650 $t Molecular medicine reports $x 1791-3004 $g Roč. 23, č. 2 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33300056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20240716102515 $b ABA008
999    __
$a ok $b bmc $g 1690235 $s 1139807
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 2 $e 20201210 $i 1791-3004 $m Molecular medicine reports $n Mol Med Rep $x MED00181650
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

    Možnosti archivace